Compare · ILMN vs QSI
ILMN vs QSI
Side-by-side comparison of Illumina Inc. (ILMN) and Quantum-Si Incorporated (QSI): market cap, price performance, sector, and recent activity on the wire.
Summary
- ILMN operates in Health Care, while QSI operates in Industrials - the two are in different parts of the market.
- ILMN is the larger of the two at $31.30B, about 123.9x QSI ($252.7M).
- Over the past year, ILMN is up 71.8% and QSI is down 16.5% - ILMN leads by 88.2 points.
- ILMN has been more active in the news (16 items in the past 4 weeks vs 4 for QSI).
- ILMN has more recent analyst coverage (25 ratings vs 4 for QSI).
- Company
- Illumina Inc.
- Quantum-Si Incorporated
- Price
- -
- -
- Market cap
- $31.30B
- $252.7M
- 1M return
- -22.73%
- -12.64%
- 1Y return
- +71.76%
- -16.48%
- Industry
- Medical Specialities
- Industrial Machinery/Components
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2000
- 2020
- News (4w)
- 16
- 4
- Recent ratings
- 25
- 4
Illumina Inc.
Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. It has a collaboration agreement with Geneseeq Technology Inc. to develop comprehensive in-vitro diagnostic (IVD) NGS testing kits for cancer. The company was incorporated in 1998 and is headquartered in San Diego, California.
Quantum-Si Incorporated
Quantum-Si incorporated operates first next-generation protein sequencing and genomics platform for healthcare industries. It offers a single molecule detection solution to decode the molecules of life, including sample preparation, single molecule, massively parallel, and protein identification. The company's technology has the applications in proteomics, single cell, transcriptomics, genomics, metabolomics, and drug testing and screening fields. The company is based in Guilford, Connecticut. Quantum-Si incorporated is a subsidiary of 4Catalyzer Corporation.
Latest ILMN
- Amendment: SEC Form SCHEDULE 13G/A filed by Illumina Inc.
- Director Meister Keith A. sold $61,093,041 worth of shares (280,091 units at $218.12) (SEC Form 4)
- VP, Chief Accounting Officer Ericksen Scott D sold $58,142 worth of shares (267 units at $217.76), decreasing direct ownership by 2% to 14,029 units (SEC Form 4)
- SVP, Chief Technology Officer Barnard Steven covered exercise/tax liability with 360 shares, decreasing direct ownership by 0.88% to 40,567 units (SEC Form 4)
- VP, Chief Accounting Officer Ericksen Scott D covered exercise/tax liability with 150 shares, decreasing direct ownership by 1% to 14,296 units (SEC Form 4)
- SVP, Chief People Officer Leckman Patricia covered exercise/tax liability with 208 shares, decreasing direct ownership by 0.98% to 21,120 units (SEC Form 4)
- Chief of Global Operations Pegels Kevin Carl covered exercise/tax liability with 604 shares, decreasing direct ownership by 2% to 28,434 units (SEC Form 4)
- Illumina advances MRD research portfolio with ultrasensitive duplex sequencing technology
- Director Meister Keith A. sold $66,560,212 worth of shares (281,433 units at $236.50) (SEC Form 4)
- Illumina selected to help bring precision medicine into everyday healthcare in Singapore
Latest QSI
- Quantum-Si Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- SEC Form 10-Q filed by Quantum-Si Incorporated
- Quantum-Si Incorporated filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Quantum-Si Reports Third Quarter 2026 Financial Results and Provides Business Update
- Quantum-Si to Provide a Business Update and Report Third Quarter 2026 Financial Results on November 5, 2026
- SEC Form 8-K filed by Quantum-Si Incorporated
- Quantum-Si Regains Compliance with Nasdaq Minimum Bid Price Requirement
- SEC Form 8-K filed by Quantum-Si Incorporated
- Quantum-Si Demonstrates Detection of 19 Amino Acids in Proteus™ Development Program
- Quantum-Si Incorporated filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits